Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Healthcare

Ansell Limited (ASX:ANN) Guides FY27 Adjusted EPS to USD 1.58-1.70

• Ansell Limited operates in protective gloves, clothing and safety solutions for healthcare and industrial customers in more than 100 countries.

Aditi Sarkar | 03 October 2026

4DMedical Limited (ASX:4DX) Sets FY27 Expansion Path for CT:VQ Imaging Platform

• FY27 priorities include accelerating CT:VQ adoption across US health systems and Veterans Affairs through Philips, expanding in Europe through contextflow sites, growing Australian networks and progressing the CLEAR pulmonary-embolism study..

Aditi Sarkar | 03 October 2026

Cochlear Ltd (ASX:COH) Shares Flat – FY26 Result and FY27 Outlook in Review

On 2 October 2026, Cochlear shares were trading at $130.32, down 0.02% and broadly unchanged for the session. The company's full-year results, released in August, reported lower profit and provided guidance for FY27, while the company was also affected by changes in the Septemberindexrebalance.

Sonal Goyal | 02 October 2026

Why Echo IQ Ltd (ASX:EIQ) Shares Are Suddenly Moving Today

On 2 October 2026, Echo IQ shares were trading at $0.58, up 1.75%. The movement took place during a firmer session for the local technology sector. As at 11:06 am, the S&P/ASX 200 Information Technologyindex(ASX:XIJ) was at 1,720.80, up 52.30 points or 3.13%, with …

Sonal Goyal | 02 October 2026

Island Pharmaceuticals Limited (ASX:ILA) Starts GMP Galidesivir Manufacturing for Ebola and Marburg Programs

Island Pharmaceuticals Limited (ASX:ILA) is an Australian antiviralDrug Developmentand biodefence company focused on therapies addressing viral diseases, public-health needs and biosecurity threats. Its development portfolio includes ISLA-101 and Galidesivir, a clinical-stage broad-spectrum antiviral with activity across more than 20 RNA viruses. The company has …

Sonal Goyal | 02 October 2026

Acrux (ASX:ACR) Receives $1.98 Million FY26 R&D Tax Incentive Rebate

Acrux Limited (ASX:ACR) is a specialty pharmaceutical company focused on developing and commercialising topically applied pharmaceutical products. The company has marketed several products internationally through licensing arrangements, with an emphasis on the United States market. Acrux has now received its FY26 Research and Development …

Sonal Goyal | 02 October 2026

Artrya (ASX:AYA) Signs Five-Year Salix Agreement With Huntsville Hospital Health System

The company states that regulatory and commercial activities are underway across key international markets, including the United States.

Sonal Goyal | 02 October 2026

TruScreen Group Limited (ASX:TRU) Begins CEO Transition as Martin Dillon Resigns

TruScreen Group Limited (ASX:TRU) is a medical device company that develops and manufactures AI-enabled technology for cervical cancer screening. Its TruScreen Ultra device is designed to detect abnormalities in cervical tissue in real time using optical and electrical measurements, without relying on conventional biological …

Sonal Goyal | 02 October 2026

Neuren Pharmaceuticals Limited (ASX:NEU): First Dividend Arrives as Phase 3 Investment Accelerates

Neuren Pharmaceuticals Limited (ASX:NEU) is a biopharmaceutical company developing new drug therapies for serious neurological conditions caused by genetic abnormalities or brain injury, with its shares listed on the ASX. Its 2026 half-year result shows aBusinessbalancing commercial income from trofinetide with rising investment in …

Aditi Sarkar | 01 October 2026

Ansell Limited (ASX:ANN): FY26 Margin Expansion and FY27 Earnings Guidance

For the year ended 30 June 2026, Ansell reported sales of US$2,140.2 million. Adjusted EBIT was US$321.9 million and the adjusted EBIT margin reached 15.0%. Statutory net profit attributable to shareholders was US$208.6 million, while adjustedEarnings Per Sharewere 148.6 US cents. Margins remain an …

Aditi Sarkar | 01 October 2026
Support

Hi! How can we help you today?

Loading…